Sangamo to put ‘substantially all’ assets for sale in bankruptcy, lines up Lilly and Astellas as buyers
8 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
Velocity
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
The brief
"Sangamo to put ‘substantially all’ assets for sale in bankruptcy, lines up Lilly and Astellas as buyers" is generating significant coverage in the Business category, with 8 articles from 8 distinct sources tracked by PULSE so far.
Outlets currently covering the story include marketscreener.com, FirstWord Pharma, The Business Journals and citybiz. PULSE measures a story's velocity from how quickly new articles appear and how many independent newsrooms join the coverage.
This brief was generated by PULSE's extractive engine from coverage metadata only. The latest headlines from every source are listed below; the velocity chart shows how the story is developing in real time.
Generated by PULSE's extractive engine from coverage metadata only — no AI-written claims. Updated 90d ago.
Quick answers
Why is "Sangamo to put ‘substantially all’ assets for sale in bankruptcy, lines up Lilly" trending?
Because 8 independent news sources published 8 articles about it in a short window — a coverage burst PULSE classifies as a trend.
How does PULSE measure this trend?
PULSE scores velocity from the rate of new articles weighted by source diversity, snapshotted hourly. The full method is public on our methodology page.
Is this trend still active?
The status badge on this page updates hourly: rising, peaking, cooling, or archived once coverage stops for 48 hours.
Coverage (8)
- Sangamo Therapeutics, Inc. Filed for Bankruptcy marketscreener.com · 93d ago
- Lilly, Astellas bid on Sangamo's assets after bankruptcy filing FirstWord Pharma · 93d ago
- Sangamo Therapeutics files for bankruptcy as Lilly and Astellas split assets The Business Journals · 93d ago
- Sangamo Therapeutics Files for Chapter 11 Bankruptcy Protection citybiz · 93d ago
- Gene Therapy Developer Sangamo Hits Ch. 11 With Sale Plans Law360 · 93d ago
- Sangamo Therapeutics Sets Stalking Horse Sales: $50M to Eli Lilly, Up to $50M to Astellas TradingView · 93d ago
- UPDATE: Lilly, Astellas circle Sangamo assets as biotech files for bankruptcy BioSpace · 93d ago
- Sangamo to put ‘substantially all’ assets for sale in bankruptcy, lines up Lilly and Astellas as buyers Fierce Biotech · 93d ago
Topics
Related trends
Eli Lilly CEO reveals astonishing shift in GLP-1 pill market
2 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
GLP-1 makers Novo, Eli Lilly sued over sudden loss of vision in patients
6 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
Eli Lilly CEO says 700,000 new seniors have started GLP-1s after Medicare coverage, and 70% are on Lilly drugs
5 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
Eli Lilly is breaking ground in Houston on a facility planned for 2030
Eli Lilly plans a 2030 groundbreaking in Houston as weight-loss drug developers line up to tap a lucrative and increasingly competitive market.
Novo says CagriSema shows greater weight loss than Lilly rival in diabetes patients
6 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
Eli Lilly CEO tells CNBC one-third of new GLP-1 pill patients are taking Foundayo, as drugmaker ramps up production
6 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.